Paratek Pharmaceuticals to Present at the Credit Suisse 31st Annual Healthcare Conference

Rhea-AI Summary

BOSTON, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) has announced that CEO Evan Loh will present at the Credit Suisse 31^st Annual Healthcare Conference from Nov. 7-10. The presentation will be available on-demand starting Nov. 8 on the company's website. Paratek focuses on developing novel therapies for life-threatening diseases, with its lead product, NUZYRA®, approved for treating community-acquired bacterial pneumonia and acute bacterial skin infections. The company is also exploring NUZYRA for nontuberculous mycobacterial pulmonary disease.

BOSTON, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, announces that Evan Loh, M.D., chief executive officer, will present at the Credit Suisse 31^st Annual Healthcare Conference held Nov. 7-10.

Dr. Loh’s presentation will be available on-demand beginning Nov. 8 under “Presentations & Events" in the Investors section of the company's website. https://www.paratekpharma.com/investor-relations

About Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use.

The company's lead commercial product, NUZYRA® (omadacycline), is a once-daily oral and intravenous antibiotic available in the United States for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). Paratek has a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights.

Paratek is also conducting a Phase 2b study with NUZYRA in a rare disease, nontuberculous mycobacterial (NTM) pulmonary disease, caused by Mycobacterium abscessus complex. Paratek estimates this opportunity represents a potential $1 billion addressable market in the United States.

Paratek exclusively licensed U.S. rights and rights to the greater China territory for Seysara® (sarecycline), a once-daily oral therapy for the treatment of moderate to severe acne vulgaris, to Almirall, LLC. Paratek retains the development and commercialization rights for sarecycline in the rest of the world.

In 2019, Paratek was awarded a contract from the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA), now valued at up to $304 million, to support the development and U.S.-based manufacturing of NUZYRA for pulmonary anthrax.

For more information, visit www.ParatekPharma.com or follow us on LinkedIn and Twitter.

Forward Looking Statements
This press release contains forward-looking statements. All statements, other than statements of historical facts, included in this press release are forward-looking statements, and are identified by words such as "advancing," "expect," "look forward," "anticipate," "continue," and other words and terms of similar meaning. These forward-looking statements are based upon our current expectations and involve substantial risks and uncertainties. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in our forward-looking statements and you should not place undue reliance on these forward-looking statements. Our actual results and the timing of events could differ materially from those included in such forward-looking statements as a result of these risks and uncertainties. These and other risk factors are discussed under "Risk Factors" and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2021 and our other filings with the Securities and Exchange Commission. We expressly disclaim any obligation or undertaking to update or revise any forward-looking statements contained herein.

CONTACTS:

For Investors:
Hans Vitzthum
LifeSci Advisors
ir@ParatekPharma.com 
Phone: 617-430-7578

For Media:
Christine Fanelle
Scient PR
Christine@scientpr.com 
Phone: 215-595-5211

FAQ

When is Paratek Pharmaceuticals presenting at the Credit Suisse Annual Healthcare Conference?

Paratek Pharmaceuticals will present at the Credit Suisse 31st Annual Healthcare Conference from Nov. 7-10, 2022.

What is the ticker symbol for Paratek Pharmaceuticals?

The ticker symbol for Paratek Pharmaceuticals is PRTK.

Where can I watch the presentation by Paratek's CEO?

Evan Loh's presentation will be available on-demand on the Paratek website starting Nov. 8, 2022.

What is NUZYRA and what conditions does it treat?

NUZYRA (omadacycline) is an antibiotic approved for treating community-acquired bacterial pneumonia and acute bacterial skin infections.

What is the potential market size for Paratek's NUZYRA in NTM pulmonary disease?

Paratek estimates the addressable market for NUZYRA in treating nontuberculous mycobacterial pulmonary disease could reach $1 billion in the U.S.